Koninklijke Philips N.v. · EURONEXT:PHIA
Koninklijke Philips — Koninklijke Philips N.V. NY Registry Shares — Q3 2025 Earnings Presentation
28 slides from Koninklijke Philips's earnings presentation, Nov 4, 2025
Slide 1: Third quarter 2025 results
Third quarter 2025 results Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer November 4, 2025
Slide 2: Table of contents
Table of contents Third quarter 2025 performance 4 2025 outlook 19 Financial appendix 23 2 © Koninklijke Philips N.V.
Slide 3: Important information
Important information Forward-looking statements and other important information This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and
Slide 4: Key takeaways
Numbers updated Key takeaways Red text = old/not updated/not final Q3 highlights • Comparable Order Intake up 8%, driven by sustained double-digit growth in North America; order book increased 6% year-on-year • Comparable Sales Growth up 3%, with growth across all three businesses • Adjusted EBITA m
Slide 5: Continued order intake growth, combined with robust order book, positions us well to deliver
Continued order intake growth, combined with robust order book, positions us well to deliver on full-year sales outlook Comparable equipment order intake growth1 Indexed equipment order book1 development 10% 8% 8% 6% 4% 2% 0% 0% -2% -2% In the quarter Rolling last twelve months -4% Q3 2024 Q4 2024 Q
Slide 6: Connected Care: Ecosystem platform of choice for patient monitoring, trusted by major hospitals
Connected Care: Ecosystem platform of choice for patient monitoring, trusted by major hospitals and industry partners Key partnerships signed in Q3 2025 Long-term partnerships with US and European hospitals Rady Children’s Hospital, San Diego adopting EMaaS to enhance efficiency with advanced monito
Slide 7: New innovation: Driving long-term momentum in hospitals through sustained innovation investment
New innovation: Driving long-term momentum in hospitals through sustained innovation investment Ultrasound Magnetic Resonance Transcend Plus BlueSeal MR RT1 launched Delivering in North America breakthrough image Expanding our leadership quality with 26 FDA- in sustainable MR for cleared cardiovascu
Slide 8: New innovation: Reinforcing leadership in Personal Health through consumer-winning innovation
New innovation: Reinforcing leadership in Personal Health through consumer-winning innovation and retail partnerships i9000 Prestige Ultra Walmart exclusive Sonicare 6000 Lumea IPL launched in North Norelco Head Shaver Pro Series Recognized by TIME as one of the and 6400 electric toothbrushes Americ
Slide 9: Global hospital demand and consumer sentiment
Global hospital demand and consumer sentiment North America Europe Greater China Rest of world Strong Stable Cautious near term; strong Solid Health underlying demand Systems1 Key drivers Productivity and Productivity and • Impact of anti-corruption Infrastructure consolidation digitalization act, c
Slide 10: Diagnosis & Treatment: AI-powered imaging and interventional platforms with intuitive workflows
Diagnosis & Treatment: AI-powered imaging and interventional platforms with intuitive workflows Image-Guided Therapy Ultrasound Azurion 7 EPIQ CVx High-end platform Premium cardiovascular designed for complex ultrasound system with clinical areas such as powerful AI-based cardiology, vascular, and c
Slide 11: Diagnosis & Treatment
Diagnosis & Treatment NOTE FROM ZOW: Option A Financial performance In millions of EUR Q3 Q3 unless otherwise stated 2024 2025 Sales 2,150 2,080 Comparable sales growth -1% 1% Adj. EBITA margin 12.6% 11.8% Income from operations 232 200 Q3 2025 highlights • 1% sales growth driven by solid Image-Guid
Slide 12: Connected Care: Efficient, interoperable monitoring and a real-time data platform
Connected Care: Efficient, interoperable monitoring and a real- time data platform spanning different care settings Hospital Patient Monitoring IntelliVue MX monitors AI-powered PIC iX central Modular, scalable monitoring monitoring platform across the entire patient care Seamlessly connecting data
Slide 13: Connected Care
Connected Care Financial performance In millions of EUR Q3 Q3 unless otherwise stated 2024 2025 Sales 1,211 1,200 Comparable sales growth 0% 5% Adj. EBITA margin 7.3% 11.4% Income from operations -17 12 Q3 2025 highlights • 5% sales growth driven by double-digit growth in Monitoring partly offset by
Slide 14: Personal Health: Innovation-led momentum fueled by premium products, sell-out trends
Personal Health: Innovation-led momentum fueled by premium products, sell-out trends, and marketing investments Personal Care Oral Health Care OneBlade 360 All in One New hybrid trimmer shaving category; One tool, ultimate 100+ million precision, for face, blades & 50+ hair and body million handles
Slide 15: Personal Health
Personal Health NOTE FROM ZOW: Option A Financial performance In millions of EUR Q3 Q3 unless otherwise stated 2024 2025 Sales 835 883 Comparable sales growth -5% 11% Adj. EBITA margin 16.5% 17.1% Income from operations 132 143 Q3 2025 highlights • 11% sales growth driven by all three businesses – G
Slide 16: Delivered a step up in sales growth, margin expansion and solid free cash flow
Delivered a step up in sales growth, margin expansion and solid free cash flow generation Q3 2025 vs. Q3 2024 In millions of EUR unless otherwise stated Sales Adjusted EBITA Free Cash Flow 4,302 531 172 Adjusted EBITA margin Year-on-year improvement Comparable Sales Growth 3.3% 12.3%, +50 bps +150 •
Slide 17: Adjusted EBITA margin driven by sales growth and productivity measures
Adjusted EBITA margin driven by sales growth and productivity measures more than offsetting cost inflation and tariffs Group Adj. EBITA margin1 + 50 bps 3.5% -3.6% 0.6% 0.0% Incl. impact from royalty income phasing of -0.7% 11.8% 11.8% 12.4% 12.3% 12.3% 12.3% Adj. EBITA Volume Productivity Cost infl
Slide 18: Productivity initiatives delivered EUR 566 million year-to-date; on track for EUR 800 million
Productivity initiatives delivered EUR 566 million year-to-date; on track to deliver EUR 800 million in 2025 Productivity initiatives savings1 To date In millions of EUR Q3 2025 Q1 2023-Q3 2025 • Simplified operating model Operating • R&D prioritization, reduction of corporate research projects 46 8
Slide 19: 2025 outlook
2025 outlook 19 © Koninklijke Philips N.V.
Slide 20: 2025 Outlook reiterated with Adjusted EBITA margin at upper-end of the range
2025 Outlook reiterated with Adjusted EBITA margin at upper-end of the range, with currently announced tariffs Previous 2025 outlook Updated 2025 outlook 1%-3% Reiterated: 1%-3% Comparable sales Diagnosis & Treatment slight growth; growth Diagnosis & Treatment and Connected Care growing within the r
Slide 21: Restructuring, acquisition-related charges and other items outlook
Restructuring, acquisition-related charges and other items outlook Full-year 2025 Restructuring costs • Further operating model simplification ~120 bps • Manufacturing, R&D footprint, and platform optimization vs 150 bps last year Other items • Mainly related to the Consent Decree, other quality act
Slide 22: Latest FX, below the line items and segment Other outlook
Latest FX, below the line items and segment Other outlook Q4 2025 Full year 2025 FX translation1 Diagnosis & Treatment ~(6.0)% ~(3.5)% Connected Care ~(7.0)% ~(4.0)% Personal Health ~(5.0)% ~(3.0)% Philips Group ~(6.0)% ~(3.5)% Effective tax rate 24-26% Financial income and expense (EUR million) ~(2
Slide 23: Financial appendix
Financial appendix 23 © Koninklijke Philips N.V.
Slide 24: Working capital and inventories
Working capital and inventories Group working capital1 Group inventories In millions of EUR unless otherwise stated Excluding insurance In millions of EUR unless otherwise stated as % of LTM sales2 receivable* as % of LTM sales2 19.6% 15.5% 4,500 18.6% 3,000 18.1% 11.7% 12.0% 11.9% 12.7% 17.8% 18.3%
Slide 25: Debt maturity profile and liability management
Debt maturity profile and liability management Long-term debt profile and liability management Debt maturity profile as per September 30, 2025 in billions of EUR unless otherwise stated Long-term debt1 • Total net debt position of EUR 6.5 billion 1.8 Short-term debt2 1.6 Un-utilized standby and • Ma
Slide 26: Net capital expenditures, depreciation and amortization
Net capital expenditures, depreciation and amortization In millions of EUR unless otherwise stated Q3 2024 Q3 2025 Net capital expenditures -170 -155 Depreciation -157 -147 Amortization and impairment: -133 -156 of acquired intangible assets -66 -79 of other intangible assets -67 -78 26 Note: Amount
Slide 27: Restructuring, acquisition-related charges and other items
Restructuring, acquisition-related charges and other items In millions of EUR unless otherwise stated Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Restructuring and acquisition- related charges Diagnosis & Treatment 19 25 16 97 157 14 15 6 Connected Care 17 18 19 -1 53 15 17 33 Pe
Slide 28: PHILIPS
PHILIPS
Koninklijke Philips N.V. NY Registry Shares — Q3 2025 Earnings Presentation on 6ix